LABELS · 0eb42fdc-2b82-4720-a7aa-24dbc4be869c

dantrolene sodium

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2024-03-22
Captured: 2026-09-09T23:37:39.774134+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

Dantrolene sodium has a potential for hepatotoxicity, and should not be used in conditions other than those recommended. Symptomatic hepatitis (fatal and non-fatal) has been reported at various dose levels of the drug. The incidence reported in patients taking up to 400 mg/day is much lower than in those taking doses of 800 mg or more per day. Even sporadic short courses of these higher dose levels within a treatment regimen markedly increased the risk of serious hepatic injury. Liver dysfunction as evidenced by blood chemical abnormalities alone (liver enzyme elevations) has been observed in patients exposed to dantrolene sodium for varying periods of time. Overt hepatitis has occurred at varying intervals after initiation of therapy, but has been most frequently observed between the third and twelfth month of therapy. The risk of hepatic injury appears to be greater in females, in patients over 35 years of age, and in patients taking other medication(s) in addition to dantrolene sodium . Spontaneous reports suggest a higher proportion of hepatic events with fatal outcome in elderly patients receiving dantrolene sodium . However, the majority of these cases were complicated with confounding factors such as intercurrent illnesses and/or concomitant potentially hepatotoxic medications (see Geriatric Use subsection). Dantrolene sodium should be used only in conjunction with appropriate monitoring of hepatic function including frequent determination of SGOT or SGPT. If no observable benefit is derived from the administration of dantrolene sodium after a total of 45 days, therapy should be discontinued. The lowest possible effective dose for the individual patient should be prescribed.

Indications and usage: exact source text

INDICATIONS AND USAGE In Chronic Spasticity Dantrolene sodium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrolene sodium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without dantrolene sodium. Occasionally, subtle but meaningful improvement in spasticity may occur with dantrolene sodium therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of dantrolene sodium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression. A decision to continue the administration of dantrolene sodium on a long-term basis is justified if introduction of the drug into the patient's regimen: produces a significant reduction in painful and/or disabling spasticity such as clonus, or permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of any annoying manifestation of spasticity considered important by the patient himself. In Malignant Hyperthermia Oral dantrolene sodium is also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known, or strongly suspect, malignant hyperthermia susceptible patients who require anesthesia and/or surgery. Currently accepted clinical practices in the management of such patients must still be adhered to (careful monitoring for early signs of malignant hyperthermia, minimizing exposure to triggering mechanisms and prompt use of intravenous Dantrolene Sodium and indicated supportive measures should signs of malignant hyperthermia appear); see also the package insert for Dantrium ® (dantrolene sodium) Intravenous. Oral dantrolene sodium should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia.

Full extracted label fields

application numbers

NDA017443

boxed warning exact

Dantrolene sodium has a potential for hepatotoxicity, and should not be used in conditions other than those recommended. Symptomatic hepatitis (fatal and non-fatal) has been reported at various dose levels of the drug. The incidence reported in patients taking up to 400 mg/day is much lower than in those taking doses of 800 mg or more per day. Even sporadic short courses of these higher dose levels within a treatment regimen markedly increased the risk of serious hepatic injury. Liver dysfunction as evidenced by blood chemical abnormalities alone (liver enzyme elevations) has been observed in patients exposed to dantrolene sodium for varying periods of time. Overt hepatitis has occurred at varying intervals after initiation of therapy, but has been most frequently observed between the third and twelfth month of therapy. The risk of hepatic injury appears to be greater in females, in patients over 35 years of age, and in patients taking other medication(s) in addition to dantrolene sodium . Spontaneous reports suggest a higher proportion of hepatic events with fatal outcome in elderly patients receiving dantrolene sodium . However, the majority of these cases were complicated with confounding factors such as intercurrent illnesses and/or concomitant potentially hepatotoxic medications (see Geriatric Use subsection). Dantrolene sodium should be used only in conjunction with appropriate monitoring of hepatic function including frequent determination of SGOT or SGPT. If no observable benefit is derived from the administration of dantrolene sodium after a total of 45 days, therapy should be discontinued. The lowest possible effective dose for the individual patient should be prescribed.

brand names

dantrolene sodium

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db715aef-83ca-4608-befa-8288ab4adeea

generic names

DANTROLENE SODIUM

0eb42fdc-2b82-4720-a7aa-24dbc4be869c

indications and usage exact

INDICATIONS AND USAGE In Chronic Spasticity Dantrolene sodium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrolene sodium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without dantrolene sodium. Occasionally, subtle but meaningful improvement in spasticity may occur with dantrolene sodium therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of dantrolene sodium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression. A decision to continue the administration of dantrolene sodium on a long-term basis is justified if introduction of the drug into the patient's regimen: produces a significant reduction in painful and/or disabling spasticity such as clonus, or permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of any annoying manifestation of spasticity considered important by the patient himself. In Malignant Hyperthermia Oral dantrolene sodium is also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known, or strongly suspect, malignant hyperthermia susceptible patients who require anesthesia and/or surgery. Currently accepted clinical practices in the management of such patients must still be adhered to (careful monitoring for early signs of malignant hyperthermia, minimizing exposure to triggering mechanisms and prompt use of intravenous Dantrolene Sodium and indicated supportive measures should signs of malignant hyperthermia appear); see also the package insert for Dantrium ® (dantrolene sodium) Intravenous. Oral dantrolene sodium should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia.

indications and usage tables exact

is original packager

manufacturer names

Bryant Ranch Prepack

matched search terms

malignant

package ndcs

63629-2169-1

product ndcs

63629-2169

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

856660

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00000.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA017443

brand names

dantrolene sodium

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 450
end exclusive: true
exact text: INDICATIONS AND USAGE In Chronic Spasticity Dantrolene sodium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of sp
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 0

current approval status

not_reconciled

duplicate text group

dup-209b48e53a23b80dfdc6

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-714f0897af8ec4c3e7d0

label id

0eb42fdc-2b82-4720-a7aa-24dbc4be869c

positive predicate support span

end: 74
end exclusive: true
exact text: is indicated
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 62

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 250
end exclusive: true
exact text: INDICATIONS AND USAGE In Chronic Spasticity Dantrolene sodium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis).
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%220eb42fdc-2b82-4720-a7aa-24dbc4be869c%22

spl effective date

2024-03-22

spl set id

db715aef-83ca-4608-befa-8288ab4adeea

spl version

106

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · unclassified context

application numbers

NDA017443

brand names

dantrolene sodium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 574
end exclusive: true
exact text: ene sodium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrolene sodium is not indicated in the treatment of skeletal muscle spa
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 51

current approval status

not_reconciled

duplicate text group

dup-b8fd2c1c0cb5d9559fa8

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-cb1a85bc46addcaee31a

label id

0eb42fdc-2b82-4720-a7aa-24dbc4be869c

positive predicate support span

Source null

qualifier mentions

context exact
fit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity.
kind
biomarker
polarity
not_inferred
span
end
373
end exclusive
true
exact text
retarded by the sequelae of spasticity
label id
0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start
335

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 374
end exclusive: true
exact text: It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity.
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 251

source url

https://api.fda.gov/drug/label.json?search=id%3A%220eb42fdc-2b82-4720-a7aa-24dbc4be869c%22

spl effective date

2024-03-22

spl set id

db715aef-83ca-4608-befa-8288ab4adeea

spl version

106

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA017443

brand names

dantrolene sodium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 699
end exclusive: true
exact text: (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrolene sodium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAG
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 175

current approval status

not_reconciled

duplicate text group

dup-d1b6c0e999b8fd83a474

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-e612c3711e1600e22918

label id

0eb42fdc-2b82-4720-a7aa-24dbc4be869c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 499
end exclusive: true
exact text: Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function.
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 375

source url

https://api.fda.gov/drug/label.json?search=id%3A%220eb42fdc-2b82-4720-a7aa-24dbc4be869c%22

spl effective date

2024-03-22

spl set id

db715aef-83ca-4608-befa-8288ab4adeea

spl version

106

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · limitation of use

application numbers

NDA017443

brand names

dantrolene sodium

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 812
end exclusive: true
exact text: functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrolene sodium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to res
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 300

current approval status

not_reconciled

duplicate text group

dup-da72345857d932eb772c

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-0732c184060dbf3b3477

label id

0eb42fdc-2b82-4720-a7aa-24dbc4be869c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 612
end exclusive: true
exact text: Dantrolene sodium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders.
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 500

source url

https://api.fda.gov/drug/label.json?search=id%3A%220eb42fdc-2b82-4720-a7aa-24dbc4be869c%22

spl effective date

2024-03-22

spl set id

db715aef-83ca-4608-befa-8288ab4adeea

spl version

106

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 5 · unclassified context

application numbers

NDA017443

brand names

dantrolene sodium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1080
end exclusive: true
exact text: ersible spasticity where relief of spasticity will aid in restoring residual function. Dantrolene sodium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without dantrolene sodium. Occasionally, subtle but meaningful improvement in spasticity may occur with dantrolene sodium therapy. In such instances, information regarding improvement should be solicited from the patient and t
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 413

current approval status

not_reconciled

duplicate text group

dup-bbf592ed080f368ef37d

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-eeac721e9603bc5596f5

label id

0eb42fdc-2b82-4720-a7aa-24dbc4be869c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 880
end exclusive: true
exact text: If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without dantrolene sodium.
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 613

source url

https://api.fda.gov/drug/label.json?search=id%3A%220eb42fdc-2b82-4720-a7aa-24dbc4be869c%22

spl effective date

2024-03-22

spl set id

db715aef-83ca-4608-befa-8288ab4adeea

spl version

106

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

NDA017443

brand names

dantrolene sodium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1184
end exclusive: true
exact text: tration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without dantrolene sodium. Occasionally, subtle but meaningful improvement in spasticity may occur with dantrolene sodium therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of dantrolene sodium fo
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 681

current approval status

not_reconciled

duplicate text group

dup-f0b9964a768d71048ce1

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-fa6e2b8bb85d837d6505

label id

0eb42fdc-2b82-4720-a7aa-24dbc4be869c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 984
end exclusive: true
exact text: Occasionally, subtle but meaningful improvement in spasticity may occur with dantrolene sodium therapy.
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 881

source url

https://api.fda.gov/drug/label.json?search=id%3A%220eb42fdc-2b82-4720-a7aa-24dbc4be869c%22

spl effective date

2024-03-22

spl set id

db715aef-83ca-4608-befa-8288ab4adeea

spl version

106

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA017443

brand names

dantrolene sodium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1343
end exclusive: true
exact text: city and the ability to resume a daily function not quite attainable without dantrolene sodium. Occasionally, subtle but meaningful improvement in spasticity may occur with dantrolene sodium therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of dantrolene sodium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression. A decisi
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 785

current approval status

not_reconciled

duplicate text group

dup-a1eafafc57697b3ae641

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-02fce131768822c7d238

label id

0eb42fdc-2b82-4720-a7aa-24dbc4be869c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1143
end exclusive: true
exact text: In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him.
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 985

source url

https://api.fda.gov/drug/label.json?search=id%3A%220eb42fdc-2b82-4720-a7aa-24dbc4be869c%22

spl effective date

2024-03-22

spl set id

db715aef-83ca-4608-befa-8288ab4adeea

spl version

106

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

NDA017443

brand names

dantrolene sodium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1534
end exclusive: true
exact text: ay occur with dantrolene sodium therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of dantrolene sodium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression. A decision to continue the administration of dantrolene sodium on a long-term basis is justified if introduction of the drug into the patient's regimen: produces a significant reduction in painful an
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 944

current approval status

not_reconciled

duplicate text group

dup-45c6a3eee1f5cc3640bc

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-e0db7e95d010247d9aa0

label id

0eb42fdc-2b82-4720-a7aa-24dbc4be869c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1334
end exclusive: true
exact text: Brief withdrawal of dantrolene sodium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression.
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 1144

source url

https://api.fda.gov/drug/label.json?search=id%3A%220eb42fdc-2b82-4720-a7aa-24dbc4be869c%22

spl effective date

2024-03-22

spl set id

db715aef-83ca-4608-befa-8288ab4adeea

spl version

106

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

NDA017443

brand names

dantrolene sodium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1976
end exclusive: true
exact text: ith him. Brief withdrawal of dantrolene sodium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression. A decision to continue the administration of dantrolene sodium on a long-term basis is justified if introduction of the drug into the patient's regimen: produces a significant reduction in painful and/or disabling spasticity such as clonus, or permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of any annoying manifestation of spasticity considered important by the patient himself. In Malignant Hyperthermia Oral dantrolene sodium is also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known, or strongly suspect, malignant h
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 1135

current approval status

not_reconciled

duplicate text group

dup-7ae618feaa19aae6c134

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-15da2c8cabd16d12f7bb

label id

0eb42fdc-2b82-4720-a7aa-24dbc4be869c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1776
end exclusive: true
exact text: A decision to continue the administration of dantrolene sodium on a long-term basis is justified if introduction of the drug into the patient's regimen: produces a significant reduction in painful and/or disabling spasticity such as clonus, or permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of any annoying manifestation of spasticity considered important by the patient himself.
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 1335

source url

https://api.fda.gov/drug/label.json?search=id%3A%220eb42fdc-2b82-4720-a7aa-24dbc4be869c%22

spl effective date

2024-03-22

spl set id

db715aef-83ca-4608-befa-8288ab4adeea

spl version

106

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · positive indication candidate

application numbers

NDA017443

brand names

dantrolene sodium

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2247
end exclusive: true
exact text: r permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of any annoying manifestation of spasticity considered important by the patient himself. In Malignant Hyperthermia Oral dantrolene sodium is also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known, or strongly suspect, malignant hyperthermia susceptible patients who require anesthesia and/or surgery. Currently accepted clinical practices in the management of such patients must still be adhered to (careful monitoring for early signs of malignant hyperthermia, minimizing exposure to triggering mech
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 1577

current approval status

not_reconciled

duplicate text group

dup-ecb9b17f47f4cf102c71

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-ef7a4ba50517a4e44aae

label id

0eb42fdc-2b82-4720-a7aa-24dbc4be869c

positive predicate support span

end: 1843
end exclusive: true
exact text: is also indicated
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 1826

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2047
end exclusive: true
exact text: In Malignant Hyperthermia Oral dantrolene sodium is also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known, or strongly suspect, malignant hyperthermia susceptible patients who require anesthesia and/or surgery.
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 1777

source url

https://api.fda.gov/drug/label.json?search=id%3A%220eb42fdc-2b82-4720-a7aa-24dbc4be869c%22

spl effective date

2024-03-22

spl set id

db715aef-83ca-4608-befa-8288ab4adeea

spl version

106

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 11 · unclassified context

application numbers

NDA017443

brand names

dantrolene sodium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2609
end exclusive: true
exact text: peratively to prevent or attenuate the development of signs of malignant hyperthermia in known, or strongly suspect, malignant hyperthermia susceptible patients who require anesthesia and/or surgery. Currently accepted clinical practices in the management of such patients must still be adhered to (careful monitoring for early signs of malignant hyperthermia, minimizing exposure to triggering mechanisms and prompt use of intravenous Dantrolene Sodium and indicated supportive measures should signs of malignant hyperthermia appear); see also the package insert for Dantrium ® (dantrolene sodium) Intravenous. Oral dantrolene sodium should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia.
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 1848

current approval status

not_reconciled

duplicate text group

dup-9680b937b167abbfe582

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-de447b31f3314cc201c9

label id

0eb42fdc-2b82-4720-a7aa-24dbc4be869c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2459
end exclusive: true
exact text: Currently accepted clinical practices in the management of such patients must still be adhered to (careful monitoring for early signs of malignant hyperthermia, minimizing exposure to triggering mechanisms and prompt use of intravenous Dantrolene Sodium and indicated supportive measures should signs of malignant hyperthermia appear); see also the package insert for Dantrium ® (dantrolene sodium) Intravenous.
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 2048

source url

https://api.fda.gov/drug/label.json?search=id%3A%220eb42fdc-2b82-4720-a7aa-24dbc4be869c%22

spl effective date

2024-03-22

spl set id

db715aef-83ca-4608-befa-8288ab4adeea

spl version

106

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · unclassified context

application numbers

NDA017443

brand names

dantrolene sodium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2609
end exclusive: true
exact text: ompt use of intravenous Dantrolene Sodium and indicated supportive measures should signs of malignant hyperthermia appear); see also the package insert for Dantrium ® (dantrolene sodium) Intravenous. Oral dantrolene sodium should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia.
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 2260

current approval status

not_reconciled

duplicate text group

dup-7a5cac2e97442ba42e44

extraction review status

automated_candidate_pending_source_review

generic names

DANTROLENE SODIUM

ind-span-2a98880f57804f89998b

label id

0eb42fdc-2b82-4720-a7aa-24dbc4be869c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2609
end exclusive: true
exact text: Oral dantrolene sodium should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia.
label id: 0eb42fdc-2b82-4720-a7aa-24dbc4be869c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7ae3a09971cc68e3643ceed8f0d4e51227284009d938f6b9c973cb996d7e2045
start: 2460

source url

https://api.fda.gov/drug/label.json?search=id%3A%220eb42fdc-2b82-4720-a7aa-24dbc4be869c%22

spl effective date

2024-03-22

spl set id

db715aef-83ca-4608-befa-8288ab4adeea

spl version

106

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice